What makes a compliant Phase III and pre-launch patient advocacy strategy?
about
What makes a compliant Phase III and pre-launch patient advocacy strategy?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 December 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
What makes a compliant Phase III and pre-launch patient advocacy strategy?
@en
What makes a compliant Phase III and pre-launch patient advocacy strategy?
@nl
type
label
What makes a compliant Phase III and pre-launch patient advocacy strategy?
@en
What makes a compliant Phase III and pre-launch patient advocacy strategy?
@nl
prefLabel
What makes a compliant Phase III and pre-launch patient advocacy strategy?
@en
What makes a compliant Phase III and pre-launch patient advocacy strategy?
@nl
P2093
P2860
P356
P1476
What makes a compliant Phase III and pre-launch patient advocacy strategy?
@en
P2093
Christoph Thalheim
Keith Allan
Nick Hicks
Paul Woods
P2860
P356
10.3402/JMAHP.V4.33177
P577
2016-12-13T00:00:00Z